XML 53 R41.htm IDEA: XBRL DOCUMENT v3.20.4
Note 2 - Acquisitions (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Mar. 31, 2020
Feb. 14, 2020
Feb. 13, 2020
Nov. 01, 2019
Jun. 30, 2020
Jan. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Jun. 30, 2020
Gain (Loss) from Change in Fair Value of CVR                 $ (899,987)  
Innovus Pharmaceuticals [Member]                      
Noncontrolling Interest, Ownership Percentage by Parent     100.00%                
The Pediatric Portfolio [Member]                      
Payments to Acquire Businesses, Gross       $ 4,500,000              
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)       9,805,845              
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Minimum Annual Royalties       $ 1,800,000              
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total       $ 22,700,000              
Finite-Lived Intangible Asset, Useful Life (Year)       10 years              
The Pediatric Portfolio [Member] | Minimum [Member]                      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Royalty Payments, Percentage of Revenues       12.00%              
The Pediatric Portfolio [Member] | Maximum [Member]                      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Royalty Payments, Percentage of Revenues       15.00%              
The Pediatric Portfolio [Member] | Cerecor, Inc. [Member]                      
Business Combination, Consideration Transferred, Liabilities Incurred, Medicaid Rebates       $ 2,700,000              
Business Combination, Consideration Transferred, Liabilities Incurred, Product Returns       800,000              
Business Combination, Consideration Transferred, Liabilities Incurred       3,500,000              
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Fixed and Variable Payments to Investor       25,600,000              
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Fixed Monthly Payments to Investor       100,000              
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Fixed Monthly Payments to Investor       $ 15,000,000              
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Monthly Variable Payments to Investor, Percentage of Revenues       15.00%              
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Monthly Minimum Variable Payments to Investor       $ 100,000              
Payments for Variable Monthly Obligation to Investor           $ 200,000          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities, Variable Payments to Investor       $ 9,500,000              
Payments for Fixed Obligations to Investor         $ 15,000,000            
The Pediatric Portfolio [Member] | Series G Preferred Stock [Member]                      
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)       980,000              
Innovus Pharmaceuticals [Member]                      
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)   3,810,393 380,000                
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total   $ 11,744,000 $ 11,700,000                
Business Combination, Consideration Transferred, Contingent Value Rights   7,049,079 16,000,000                
Stock Issued During Period, Shares, Contingent Value Rights (in shares) 120,000                    
Stock Issued During Period, Value, Contingent Value Rights $ 2,000,000                    
Business Combination, Contingent Value Rights, First Revenue Milestone 24,000,000                    
Gain (Loss) from Change in Fair Value of CVR $ 300,000           $ (100,000) $ (100,000) (800,000) $ (800,000) $ 300,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt     3,100,000                
Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation   $ 754,822 800,000                
Innovus Pharmaceuticals [Member] | Notes Payable, Other Payables [Member]                      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt             $ 41,000   $ 41,000    
Innovus Pharmaceuticals [Member] | Conversion of Notes Payable into Common Stock [Member]                      
Debt Conversion, Original Debt, Amount     $ 2,200,000                
Debt Conversion, Converted Instrument, Shares Issued (in shares)     180,000                
Innovus Pharmaceuticals [Member] | Minimum [Member]                      
Finite-Lived Intangible Asset, Useful Life (Year)     1 year 182 days                
Innovus Pharmaceuticals [Member] | Maximum [Member]                      
Finite-Lived Intangible Asset, Useful Life (Year)     10 years                
Innovus Pharmaceuticals [Member] | Series H Preferred Stock [Member]                      
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)   1,997,736                  
Stock Issued During Period, Shares, Exercise of Warrants (in shares)     200,000